Cargando…
Effect of prenatal DHA supplementation on the infant epigenome: results from a randomized controlled trial
BACKGROUND: Evidence is accumulating that nutritional exposures in utero can influence health outcomes in later life. Animal studies and human epidemiological studies have implicated epigenetic modifications as playing a key role in this process, but there are limited data from large well-controlled...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096291/ https://www.ncbi.nlm.nih.gov/pubmed/27822319 http://dx.doi.org/10.1186/s13148-016-0281-7 |
_version_ | 1782465443157508096 |
---|---|
author | van Dijk, Susan J. Zhou, Jing Peters, Timothy J. Buckley, Michael Sutcliffe, Brodie Oytam, Yalchin Gibson, Robert A. McPhee, Andrew Yelland, Lisa N. Makrides, Maria Molloy, Peter L. Muhlhausler, Beverly S. |
author_facet | van Dijk, Susan J. Zhou, Jing Peters, Timothy J. Buckley, Michael Sutcliffe, Brodie Oytam, Yalchin Gibson, Robert A. McPhee, Andrew Yelland, Lisa N. Makrides, Maria Molloy, Peter L. Muhlhausler, Beverly S. |
author_sort | van Dijk, Susan J. |
collection | PubMed |
description | BACKGROUND: Evidence is accumulating that nutritional exposures in utero can influence health outcomes in later life. Animal studies and human epidemiological studies have implicated epigenetic modifications as playing a key role in this process, but there are limited data from large well-controlled human intervention trials. This study utilized a large double-blind randomized placebo-controlled trial to test whether a defined nutritional exposure in utero, in this case docosahexaenoic acid (DHA), could alter the infant epigenome. Pregnant mothers consumed DHA-rich fish oil (800 mg DHA/day) or placebo supplements from 20 weeks’ gestation to delivery. Blood spots were collected from the children at birth (n = 991) and blood leukocytes at 5 years (n = 667). Global DNA methylation was measured in all samples, and Illumina HumanMethylation450K BeadChip arrays were used for genome-wide methylation profiling in a subset of 369 children at birth and 65 children at 5 years. RESULTS: There were no differences in global DNA methylation levels between the DHA and control group either at birth or at 5 years, but we identified 21 differentially methylated regions (DMRs) at birth, showing small DNA methylation differences (<5%) between the treatment groups, some of which seemed to persist until 5 years. The number of DMRs at birth was greater in males (127 DMRs) and in females (72 DMRs) separately, indicating a gender-specific effect. CONCLUSION: Maternal DHA supplementation during the second half of pregnancy had small effects on DNA methylation of infants. While the potential functional significance of these changes remains to be determined, these findings further support the role of epigenetic modifications in developmental programming in humans and point the way for future studies. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry (ANZCTR), ACTRN12605000569606 and ACTRN12611001127998 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-016-0281-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5096291 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-50962912016-11-07 Effect of prenatal DHA supplementation on the infant epigenome: results from a randomized controlled trial van Dijk, Susan J. Zhou, Jing Peters, Timothy J. Buckley, Michael Sutcliffe, Brodie Oytam, Yalchin Gibson, Robert A. McPhee, Andrew Yelland, Lisa N. Makrides, Maria Molloy, Peter L. Muhlhausler, Beverly S. Clin Epigenetics Research BACKGROUND: Evidence is accumulating that nutritional exposures in utero can influence health outcomes in later life. Animal studies and human epidemiological studies have implicated epigenetic modifications as playing a key role in this process, but there are limited data from large well-controlled human intervention trials. This study utilized a large double-blind randomized placebo-controlled trial to test whether a defined nutritional exposure in utero, in this case docosahexaenoic acid (DHA), could alter the infant epigenome. Pregnant mothers consumed DHA-rich fish oil (800 mg DHA/day) or placebo supplements from 20 weeks’ gestation to delivery. Blood spots were collected from the children at birth (n = 991) and blood leukocytes at 5 years (n = 667). Global DNA methylation was measured in all samples, and Illumina HumanMethylation450K BeadChip arrays were used for genome-wide methylation profiling in a subset of 369 children at birth and 65 children at 5 years. RESULTS: There were no differences in global DNA methylation levels between the DHA and control group either at birth or at 5 years, but we identified 21 differentially methylated regions (DMRs) at birth, showing small DNA methylation differences (<5%) between the treatment groups, some of which seemed to persist until 5 years. The number of DMRs at birth was greater in males (127 DMRs) and in females (72 DMRs) separately, indicating a gender-specific effect. CONCLUSION: Maternal DHA supplementation during the second half of pregnancy had small effects on DNA methylation of infants. While the potential functional significance of these changes remains to be determined, these findings further support the role of epigenetic modifications in developmental programming in humans and point the way for future studies. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry (ANZCTR), ACTRN12605000569606 and ACTRN12611001127998 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-016-0281-7) contains supplementary material, which is available to authorized users. BioMed Central 2016-11-04 /pmc/articles/PMC5096291/ /pubmed/27822319 http://dx.doi.org/10.1186/s13148-016-0281-7 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research van Dijk, Susan J. Zhou, Jing Peters, Timothy J. Buckley, Michael Sutcliffe, Brodie Oytam, Yalchin Gibson, Robert A. McPhee, Andrew Yelland, Lisa N. Makrides, Maria Molloy, Peter L. Muhlhausler, Beverly S. Effect of prenatal DHA supplementation on the infant epigenome: results from a randomized controlled trial |
title | Effect of prenatal DHA supplementation on the infant epigenome: results from a randomized controlled trial |
title_full | Effect of prenatal DHA supplementation on the infant epigenome: results from a randomized controlled trial |
title_fullStr | Effect of prenatal DHA supplementation on the infant epigenome: results from a randomized controlled trial |
title_full_unstemmed | Effect of prenatal DHA supplementation on the infant epigenome: results from a randomized controlled trial |
title_short | Effect of prenatal DHA supplementation on the infant epigenome: results from a randomized controlled trial |
title_sort | effect of prenatal dha supplementation on the infant epigenome: results from a randomized controlled trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096291/ https://www.ncbi.nlm.nih.gov/pubmed/27822319 http://dx.doi.org/10.1186/s13148-016-0281-7 |
work_keys_str_mv | AT vandijksusanj effectofprenataldhasupplementationontheinfantepigenomeresultsfromarandomizedcontrolledtrial AT zhoujing effectofprenataldhasupplementationontheinfantepigenomeresultsfromarandomizedcontrolledtrial AT peterstimothyj effectofprenataldhasupplementationontheinfantepigenomeresultsfromarandomizedcontrolledtrial AT buckleymichael effectofprenataldhasupplementationontheinfantepigenomeresultsfromarandomizedcontrolledtrial AT sutcliffebrodie effectofprenataldhasupplementationontheinfantepigenomeresultsfromarandomizedcontrolledtrial AT oytamyalchin effectofprenataldhasupplementationontheinfantepigenomeresultsfromarandomizedcontrolledtrial AT gibsonroberta effectofprenataldhasupplementationontheinfantepigenomeresultsfromarandomizedcontrolledtrial AT mcpheeandrew effectofprenataldhasupplementationontheinfantepigenomeresultsfromarandomizedcontrolledtrial AT yellandlisan effectofprenataldhasupplementationontheinfantepigenomeresultsfromarandomizedcontrolledtrial AT makridesmaria effectofprenataldhasupplementationontheinfantepigenomeresultsfromarandomizedcontrolledtrial AT molloypeterl effectofprenataldhasupplementationontheinfantepigenomeresultsfromarandomizedcontrolledtrial AT muhlhauslerbeverlys effectofprenataldhasupplementationontheinfantepigenomeresultsfromarandomizedcontrolledtrial |